Year: 2025

VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) — AIP Realty Trust (the “Trust” or “AIP”) (TSXV: AIP.U) today provides a corporate update on the progress of the execution of its expansion plans. Credit Facility: AIP has entered into a term sheet and mandate letter with a leading US banking institution to serve as the administrative agent and sole lead arranger of a senior first mortgage, secured, interest-only credit facility (the “Facility”). The total Facility will be for USD $300,000,000, with the initial amount being USD $100,000,000. The Facility will be subject to an accordion option whereby the Trust shall have the right to increase the Facility by an amount equal to an additional USD $200,000,000. Closing of the Facility will be subject to certain customary conditions precedent, and further details will be...

Projects aim to be responsive to the energy needs of data centers by offering an abundant supply of operational power within two years Projects target the provision of on-site, continuous, and scalable power generation, and securing data center uptime even in volatile market conditions The partnership would involve innovative capital structuring coupled with environmental credit cash flow generation from the fuel cell platforms and coal mine methane (CMM) Clean fuel cell technology can reduce the carbon footprint of data center and other high-volume electrical off-takers Projects aspire to create jobs and other economic benefits focused on the Appalachian region BIRMINGHAM, Ala. and DANBURY, Conn. and SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) — Diversified Energy Co. PLC (NYSE: DEC, LSE: DEC) (“Diversified Energy”), FuelCell...

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced the execution of the first lithium carbonate futures block trade, traded between Traxys and HNK Alpha on March 7, 2025. Traxys and HNK Alpha traded 20 lots of the May 2025 Abaxx Lithium Carbonate Singapore futures contract at USD$10,300/tonne. “We are delighted to be an active participant in the newly created Abaxx physical lithium carbonate contract,” said Martim Facada, Head of Lithium, Traxys. “As a long-term participant in the...

VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) announces that it has filed notice of a meeting of shareholders, a management information circular, and related documents (collectively, the “Meeting Materials”) to convene a special meeting (the “Meeting”) of shareholders. The Meeting will take place on March 31, 2025 at 10:00 AM (Vancouver Time). Copies of the Meeting Materials are available for review under the profile for the Company on SEDAR+ (www.sedarplus.ca) and on Anfield’s corporate website (https://anfieldenergy.com). The Meeting has been convened to seek shareholder approval for a consolidation (the “Consolidation”) of the Company’s common shares (“Shares”) on the basis of one new Share for up to 200 currently issued...

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The trial included 1,206 randomised people with obesity or overweight and type 2 diabetes and a mean baseline body weight of 102 kg. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial. After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose. When evaluating the...

SINGAPORE and SHANGHAI, March 10, 2025 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”) a key player in the global hotel industry, today announced that it will schedule to release its unaudited financial results for the fourth quarter and full year of 2024 on Thursday, March 20, 2025 (Hong Kong time), after the trading hours of The Stock Exchange of Hong Kong Limited and before the opening of the U.S. market. H World’s management will host a conference call at 8 a.m. (U.S. Eastern time) on Thursday, March 20, 2025 (or 8 p.m. (Hong Kong time) on Thursday, March 20, 2025) following the announcement. To join by phone, all participants must pre-register this conference call using the Participant Registration link of https://register-conf.media-server.com/register/BI303638c962504ffcb81bb09e374f8485....

SYN461x is optimized for power, system integration, size, and time to market with outstanding rate-over-range and seamless interoperability to target an ~$3.2 billion market opportunity NUREMBERG, Germany, March 10, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) has extended its award-winning Veros™ Triple Combo connectivity portfolio with the SYN461x family of ultra-low-power (ULP) Wi-Fi® 2.4/5/6 GHz, Bluetooth® 6.0 and Bluetooth Low Energy (BLE), and IEEE 802.15.4 (Zigbee®/Thread®) systems on chip (SoCs). Designed for the embedded Edge AI Internet of Things (IoT), the SYN461x is optimized for power, system integration, size, and rapid time to market while delivering Veros’ characteristic outstanding rate-over-range performance and seamless interoperability. The versatile Matter-compliant SoCs offer advanced...

Five presentations affirm positive outcomes utilizing inhaled insulin An sNDA filing for Afrezza in pediatric population anticipated in 2025DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 10, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase data from recent studies of inhaled insulin across five presentations at the 18th International Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. “Data from both the INHALE-1 pediatric and INHALE-3 adult studies continue to drive groundbreaking conversations around inhaled insulin,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area...